E. Anders Kolb: Blood Cancer United Preserves Access to Luveltamab Tazevibulin for Children with AML

oncodaily - E. Anders Kolb, Chief Executive Officer of Blood Cancer United, shared a post on LinkedIn: “Today we announced a first‑of‑its‑kind intervention from a nonprofit. Blood Cancer United has stepped up […]

AI Summary: A nonprofit stepped into a supply crisis and purchased the remaining stock of an experimental agent to preserve access for children with acute myeloid leukemia. The emergency buy protects current patients from treatment interruption while stakeholders scramble for a durable manufacturing or regulatory fix, illustrating how charities sometimes act like pharma’s safety net.